--- title: "LEMAITRE VASCULAR INC (LMAT) stock and investor profile" url: "https://aibio.space/companies/lemaitre-vascular/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "LEMAITRE VASCULAR INC (NASDAQ: LMAT), United States. Listing facts, related biotech companies and news on aibio.space." --- LMAT LEMAITRE VASCULAR INC NASDAQ · United States # LEMAITRE VASCULAR INC (LMAT) news LEMAITRE VASCULAR INC is a public biotech or pharmaceutical company listed on NASDAQ under the ticker LMAT, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. ## Latest LEMAITRE VASCULAR INC news We have not published a story on LEMAITRE VASCULAR INC yet. When there is news, it will appear here. ## LEMAITRE VASCULAR INC at a glance - **Ticker**: LMAT - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $376.2 million ### Related companies - [QHSLab](https://aibio.space/companies/qhslab/) OTC: USAQ - [MAXCYTE, INC.](https://aibio.space/companies/maxcyte/) NASDAQ: MXCT - [Anteris Technologies Global](https://aibio.space/companies/anteris-technologies-global/) NASDAQ: AVR - [ASTROTECH](https://aibio.space/companies/astrotech/) NASDAQ: ASTC - [Research Alliance Corp III](https://aibio.space/companies/research-alliance-iii/) NASDAQ: RACC - [Modular Medical](https://aibio.space/companies/modular-medical/) NASDAQ: MODD - [Nano-X Imaging](https://aibio.space/companies/nano-x-imaging/) NASDAQ: NNOX - [VIVOS INC](https://aibio.space/companies/vivos/) OTC: RDGL ### Also on NASDAQ - [Nutriband](https://aibio.space/companies/nutriband/) NTRB - [ClearPoint Neuro](https://aibio.space/companies/clearpoint-neuro/) CLPT - [IRulya Therapeutics](https://aibio.space/companies/irulya-therapeutics/) IRLA - [Bone Biologics](https://aibio.space/companies/bone-biologics/) BBLG - [Unicycive Therapeutics](https://aibio.space/companies/unicycive-therapeutics/) UNCY - [NovaBridge Biosciences](https://aibio.space/companies/novabridge-biosciences/) NBP ## LEMAITRE VASCULAR INC annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$249.6 million](https://www.sec.gov/Archives/edgar/data/1158895/000119312526073360/) | [$219.9 million](https://www.sec.gov/Archives/edgar/data/1158895/000119312526073360/) | | Research and development | [$14.1 million](https://www.sec.gov/Archives/edgar/data/1158895/000119312526073360/) | [$15.7 million](https://www.sec.gov/Archives/edgar/data/1158895/000119312526073360/) | | Net income (loss) | [$57.7 million](https://www.sec.gov/Archives/edgar/data/1158895/000119312526073360/) | [$44.0 million](https://www.sec.gov/Archives/edgar/data/1158895/000119312526073360/) | | Cash from operations | [$81.3 million](https://www.sec.gov/Archives/edgar/data/1158895/000119312526073360/) | [$44.1 million](https://www.sec.gov/Archives/edgar/data/1158895/000119312526073360/) | | Cash and equivalents | [$28.2 million](https://www.sec.gov/Archives/edgar/data/1158895/000119312526333762/) | [$25.6 million](https://www.sec.gov/Archives/edgar/data/1158895/000119312526073360/) | | Short-term investments | [$330.9 million](https://www.sec.gov/Archives/edgar/data/1158895/000119312526333762/) | [$274.1 million](https://www.sec.gov/Archives/edgar/data/1158895/000119312526073360/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $26.6 million, plus short-term investments of $349.6 million, $376.2 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about LEMAITRE VASCULAR INC What is the ticker symbol of LEMAITRE VASCULAR INC? LEMAITRE VASCULAR INC trades under the ticker LMAT on NASDAQ. Where is LEMAITRE VASCULAR INC listed? LEMAITRE VASCULAR INC is listed on NASDAQ. Which country or territory is LEMAITRE VASCULAR INC listed under? Our directory records LEMAITRE VASCULAR INC under United States. Does aibio.space cover LEMAITRE VASCULAR INC? aibio.space lists LEMAITRE VASCULAR INC among 2,820 public biotech companies and publishes its news here as stories appear. What was LEMAITRE VASCULAR INC's revenue last year? $249.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is LEMAITRE VASCULAR INC profitable? LEMAITRE VASCULAR INC reported net income of $57.7 million for the fiscal year ended Dec 31, 2025, and generated $81.3 million of cash from operations, per its annual report to the SEC. How much does LEMAITRE VASCULAR INC spend on research and development? $14.1 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does LEMAITRE VASCULAR INC have? $376.2 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: LEMAITRE VASCULAR INC Members talk about LEMAITRE VASCULAR INC (LMAT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:LMAT on TradingView](https://www.tradingview.com/symbols/NASDAQ-LMAT/). ## Listing details LEMAITRE VASCULAR INC is a public biotech or pharmaceutical company listed on NASDAQ under the ticker LMAT, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: LEMAITRE VASCULAR INC - **Ticker**: LMAT - **Listing**: NASDAQ - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/lemaitre-vascular/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "LEMAITRE VASCULAR INC (LMAT) stock and investor profile", 2026-10-31, https://aibio.space/companies/lemaitre-vascular/